Clinical Trials Logo

Clinical Trial Summary

According to the reported histological procurement yield of the end-cutting needles, the investigators supposed that the use of EUS-FNB in probable AIP patients, generally aimed only to rule-out malignancy, could provide histological tissue samples useful in enhancing the diagnostic level reached without histology, or defining the type of AIP.


Clinical Trial Description

The primary aim is to evaluate the capability of EUS-FNB to enhance diagnostic levels of AIP, that means to obtain definitive diagnosis of type 1 and type 2 AIP. Secondary aims are to evaluate: Safety of EUS-FNB in this setting of patients; the possibility to obtain a definitive diagnosis in focal/segmental form of AIP (that are the most clinically relevant because of the mimicking of cancer); diagnostic yield of EUS-FNB in this patient population; the rate of pancreatic neoplasms mimicking AIP. Consecutive patients ≥ 18 years old, with suspected focal or diffuse AIP, according to ICDC (probable type 1 AIP; probable type 2 AIP; NOS-AIP) with written consent to participate in the study will be enrolled. Exclusion criteria include: previous diagnosis of AIP; definitive type 1 AIP; steroid administration within 3 months before the EUS-FNB; coagulation disorders; pregnancy and lactation; unability to give informed consent . The histopathology of the preparations will be evaluated, according to the ICDC, including the LPSP findings and the IDCP findings and recording the absence or presence of specific criteria: Periductal lymphoplasmacytic infiltrate without GELs, Storiform fibrosis, Obliterative phlebitis >10 IgG4-positive cells per HPF; GEL of duct wall; Granulocytic and lympho- plasmacytic acinar infiltrate. According to the current clinical practice, when the diagnosis of AIP is confirmed (and malignancy is ruled-out) patient will be treated with the standard therapy for AIP. Patients will be followed for 12 months, in order to exclude misdiagnosed malignancy, and to evaluate the clinical course of the disease (response to steroid therapy, relapses, changes in imaging findings or surgical pathology in resected patients). The final diagnosis of AIP will be confirmed on surgical pathology (in resected patients) or when a compatible clinical course is observed during a follow-up of at least 1 year (significant improvement on imaging after steroid therapy, no appearance of metastasis or sign of infiltration). The number of cases where EUS-FNB histology improves the diagnostic level will be summarized using absolute and relative frequencies. The 95% confidence interval of this proportion will also be computed. The number of adverse events, the number of cases where histological finding diagnostic of AIP are observed in focal/segmental form and the number of pancreatic neoplasm will be summarized using absolute and relative frequencies. Sensitivity, specificity, positive likelihood ratio (LR+), negative likelihood Ratio (LR-) and the ROC curve will be used to analyze the capability of EUS-FNB to obtain a definitive diagnosis of type 1 and 2 AIP. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04397731
Study type Observational [Patient Registry]
Source Azienda Ospedaliera Universitaria Integrata Verona
Contact Stefano Francesco Crinò
Phone +390458126169
Email stefanofrancesco.crino@aovr.veneto.it
Status Recruiting
Phase
Start date May 1, 2020
Completion date June 1, 2023

See also
  Status Clinical Trial Phase
Recruiting NCT03753815 - Diagnostic Yield of FNA Needle and FNB Needle for Autoimmune Pancreatitis N/A
Recruiting NCT02797665 - Treatment of Obstructive Jaundice in Autoimmune Pancreatitis and/or Immunoglobulin G4-related Sclerosing Cholangitis by Corticosteroids N/A
Recruiting NCT04834505 - To Differentiate Focal Autoimmune Pancreatitis From Pancreatic Cancer by Endoscopic Ultrasound
Not yet recruiting NCT06358001 - EchoTip AcuCore Post-Market Clinical Study
Completed NCT05476978 - Artificial Intelligence in EUS for Diagnosing Pancreatic Solid Lesions
Recruiting NCT06369909 - Study on AI-assisted Multimodal Diagnosis System of Autoimmune Pancreatitis
Recruiting NCT01774513 - EUS-guided Procore-biopsy in Diagnosing Autoimmune Pancreatitis N/A
Completed NCT03241797 - Evaluation of EUS-guided FNA for Diagnosing Autoimmune Pancreatitis N/A
Completed NCT05171517 - Study on Microflora Characteristics of Pancreatic Solid Lesions Via Endoscopic Ultrasound-guided Fine Needle Aspiration/Biopsy
Withdrawn NCT01845467 - Efficacy of Secretin MRCP in the Diagnosis and Follow up of Auto Immune Pancreatitis
Completed NCT05565066 - A Real-world Comparison of FNB and FNA in IHC-required Lesions.
Withdrawn NCT02766842 - Evaluation of a New EUS Guided Biopsy Needle (SharkCore) Comparing to Standard EUS Needle (ProCore) Phase 2
Completed NCT02705638 - Treatment of IgG4-Related Disease With Revlimid and Rituximab Phase 1
Completed NCT01584388 - Rituximab in IgG4-related Disease: A Phase 1-2 Trial Phase 1/Phase 2
Completed NCT00588367 - CT Pancreas Perfusion N/A